conclusion:
In conclusion, our case shows that a single occurrence of
infusion-related reactions with crizanlizumab does not necessarily
equate to recurrence. Therefore, the long-term overall efficacy of the
drug must be considered before a decision is made to discontinue it
prematurely. In the specific case of our SCD patient, treatment with
crizanlizumab showed hopeful results in stuttering priapism, an
observation that needs to be confirmed by other similar cases and
real-world evidence.